DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,587,313 | -68.7% | 70,888 | -69.7% | 0.04% | -75.0% |
| Q2 2023 | $56,125,200 | -32.1% | 233,855 | -28.7% | 0.17% | -49.0% |
| Q1 2023 | $82,698,609 | +39.5% | 328,117 | +47.0% | 0.34% | +44.0% |
| Q4 2022 | $59,261,651 | +25892.0% | 223,275 | +24708.3% | 0.23% | +23300.0% |
| Q2 2022 | $228,000 | -97.1% | 900 | -96.6% | 0.00% | -97.0% |
| Q1 2022 | $7,797,000 | -79.3% | 26,582 | -76.8% | 0.03% | -67.0% |
| Q4 2021 | $37,749,000 | +157.9% | 114,734 | +138.7% | 0.10% | +132.6% |
| Q3 2021 | $14,635,000 | +107.1% | 48,070 | +82.6% | 0.04% | +59.3% |
| Q2 2021 | $7,065,000 | -69.5% | 26,327 | -74.4% | 0.03% | -80.1% |
| Q1 2021 | $23,160,000 | -46.1% | 102,896 | -46.8% | 0.14% | -57.6% |
| Q4 2020 | $42,991,000 | +7577.0% | 193,532 | +7343.5% | 0.32% | +3912.5% |
| Q3 2020 | $560,000 | -94.9% | 2,600 | -95.8% | 0.01% | -95.5% |
| Q2 2020 | $10,976,000 | +42.2% | 62,073 | +11.3% | 0.18% | -10.1% |
| Q1 2020 | $7,721,000 | +227.3% | 55,787 | +241.6% | 0.20% | +842.9% |
| Q3 2019 | $2,359,000 | -80.8% | 16,333 | -86.3% | 0.02% | -85.3% |
| Q4 2018 | $12,302,000 | -51.6% | 119,300 | -49.0% | 0.14% | -53.0% |
| Q3 2018 | $25,428,000 | -53.1% | 234,010 | -57.4% | 0.30% | -57.7% |
| Q2 2018 | $54,227,000 | +223.9% | 549,521 | +221.3% | 0.72% | +170.3% |
| Q1 2018 | $16,743,000 | +99.1% | 171,009 | +88.7% | 0.27% | +81.0% |
| Q4 2017 | $8,410,000 | -71.5% | 90,606 | -73.7% | 0.15% | -74.1% |
| Q3 2017 | $29,545,000 | +62.9% | 344,428 | +60.2% | 0.57% | +59.1% |
| Q2 2017 | $18,140,000 | +397.1% | 214,953 | +403.8% | 0.36% | +253.5% |
| Q1 2017 | $3,649,000 | -61.2% | 42,666 | -64.7% | 0.10% | -73.7% |
| Q4 2016 | $9,395,000 | +1293.9% | 120,699 | +1304.6% | 0.38% | +753.3% |
| Q3 2016 | $674,000 | -69.5% | 8,593 | -63.9% | 0.04% | -81.4% |
| Q4 2015 | $2,211,000 | -6.4% | 23,807 | -14.1% | 0.24% | -59.0% |
| Q3 2015 | $2,363,000 | +136.3% | 27,726 | +137.2% | 0.59% | +81.5% |
| Q2 2015 | $1,000,000 | +239.0% | 11,687 | +239.8% | 0.32% | +14.0% |
| Q4 2014 | $295,000 | – | 3,439 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |